New updates have been reported about Syneron Bio.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Syneron Bio has closed a $150 million Series B financing led by an international life sciences fund, with Decheng Capital and CDH VGC as co-leads, reinforcing its capital base for pipeline and platform expansion. The round drew participation from global institutional investors including a subsidiary of Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners, BioTrack Capital, industrial investors, and existing backers such as AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund, and Lenovo Capital.
The company plans to deploy the proceeds to enhance its Synova™ intelligent macrocyclic peptide discovery platform and to push a diversified set of oncology, autoimmune, metabolic, and rare disease programs toward and through clinical development. CEO Dr. Frank Zhang said the strengthened cash position will support scaling Synova’s high-throughput, AI-driven capabilities to improve discovery efficiency and success rates, positioning Syneron Bio as a differentiated player in macrocyclic therapeutics and broadening its potential to address high-value unmet medical needs globally.